Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.40 |
| ▸ | CDK1 | P06493 | 5/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256222 | 0.93 | CDK2 (0.44) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL3248788 | 0.93 | CDK2 (0.48) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL23021957 | 0.87 | HRH3 (0.45) | — | |
| SCHEMBL3136710 | 0.84 | HTR2B (0.43) | — | |
| SCHEMBL28163722 | 0.81 | CDK2 (0.39) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL29597929 | 0.74 | CCR4 (0.42) | MEN1KMT2ADHFR | |
| SCHEMBL3149912 | 0.74 | CCR4 (0.42) | MEN1KMT2ADHFR | |
| SCHEMBL23013102 | 0.74 | HTT (0.33) | KMT2AATR | |
| SCHEMBL28107163 | 0.74 | CDK2 (0.37) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL28031718 | 0.74 | MAP4K4 (0.39) | CDK2CCNA2CCNA1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180327396-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-15 | — | — | US | disclosed |
| EP-3126359-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2017-02-08 | — | — | EP | disclosed |
| EP-2928882-B1 | PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2928882-B1 | PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-20160376262-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160376262-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9512141-B2 | Pyrazine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512141-B2 | Pyrazine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512141-B2 | Pyrazine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2771327-B1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015150440-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150440-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | disclosed |
| EP-2771327-A1 | NOVEL PYRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-03 | — | — | EP | disclosed |
| WO-2014086807-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086807-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2013060751-A1 | NOVEL PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013060751-A1 | NOVEL PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-02 | — | — | WO | disclosed |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | CNR2, CNR1, GPR174 | CDK2 388/4885CCNA2 582/4885CCNA1 860/4885 |
| US-20180327396-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | CDK2 416/4885CCNA2 538/4885CCNA1 382/4885 |
| US-20160376262-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | CDK2 416/4885CCNA2 538/4885CCNA1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.